Climb Bio Inc (CLYM) Income Statement
CLYM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCLYM revenue and net income
CLYM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CLYM quarterly EPS vs estimates
Climb Bio beat the analyst EPS estimate in 4 of the last 7 quarters. Next report: November 5, 2026 (estimate $-0.19).
CLYM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $97,000 | — | — | — | — | — | — |
| Gross profit | −$97,000 | — | — | — | — | — | — |
| Research & development | $46.6M | $14.3M | $15.4M | $26.2M | $23.3M | $9.3M | $4.0M |
| Sales, general & admin | $21.2M | $16.0M | $24.9M | $18.9M | $12.3M | $2.4M | $677,000 |
| Total operating expenses | $67.8M | $82.0M | $40.3M | $45.1M | $35.7M | $20.9M | $7.4M |
| Operating income | −$67.9M | −$82.0M | −$40.3M | −$45.1M | −$35.7M | −$20.9M | −$7.4M |
| Interest income | $8.3M | $8.1M | $4.6M | $1.4M | — | — | — |
| Income before taxes | −$59.9M | −$73.9M | −$35.1M | −$45.2M | −$47.5M | −$20.7M | −$6.5M |
| Net income | −$59.9M | −$73.9M | −$35.1M | −$45.2M | −$47.5M | −$20.7M | −$6.5M |
| EBITDA | −$59.8M | −$30.4M | −$35.1M | −$45.2M | −$47.5M | −$11.8M | −$4.7M |
| EPS (diluted) | −$0.89 | −$1.96 | −$1.31 | −$1.72 | −$0.06 | −$1.77 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $38,000 | $30,000 | $29,000 | $38,000 | — | — | — | — | — | — | — |
| Gross profit | — | −$38,000 | −$30,000 | −$29,000 | −$38,000 | — | — | — | — | — | — | — |
| Research & development | $9.7M | $9.3M | $13.7M | $9.1M | $6.6M | $17.3M | $6.0M | $6.2M | $52.7M | $1.1M | $3.1M | $2.9M |
| Sales, general & admin | $5.6M | $5.8M | $5.6M | $5.8M | $4.1M | $5.7M | $5.0M | $5.5M | $3.7M | $1.9M | $2.0M | $2.1M |
| Total operating expenses | $15.4M | $15.2M | $19.3M | $14.9M | $10.6M | $23.0M | $10.9M | $11.7M | $56.4M | $3.0M | $5.1M | $5.0M |
| Operating income | −$15.4M | −$15.2M | −$19.3M | −$14.9M | −$10.7M | −$23.0M | −$10.9M | −$11.7M | −$56.4M | −$3.0M | −$5.1M | −$5.0M |
| Interest income | $1.9M | $1.5M | — | — | $2.2M | $2.3M | — | — | $1.5M | $1.3M | $1.3M | $1.3M |
| Income before taxes | −$13.5M | −$13.7M | −$17.5M | −$12.9M | −$8.7M | −$20.8M | −$8.4M | −$8.9M | −$54.9M | −$1.7M | −$3.6M | −$4.0M |
| Net income | −$13.5M | −$13.7M | −$17.5M | −$12.9M | −$8.7M | −$20.8M | −$8.4M | −$8.9M | −$54.9M | −$1.7M | −$3.6M | −$4.0M |
| EBITDA | −$15.3M | −$13.7M | −$17.5M | −$12.9M | −$8.6M | −$20.8M | −$8.4M | −$8.9M | −$54.9M | −$1.7M | −$3.6M | −$4.0M |
| EPS (diluted) | −$0.18 | −$0.20 | −$0.26 | −$0.19 | −$0.13 | −$0.31 | $0.04 | −$0.13 | −$1.81 | −$0.06 | −$0.13 | −$0.15 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CLYM's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CLYM financial results
Climb Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $59.9 million. Diluted earnings per share came to −$0.89.
See the CLYM stock overview for the latest quote and news, or the CLYM chart for price history and technical indicators.
CLYM income statement FAQ
Does Climb Bio have revenue?
Climb Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Climb Bio profitable?
No. Climb Bio reported a net loss of $59.9 million in fiscal 2025.
How much does Climb Bio spend on research and development?
Climb Bio spent $46.6 million on research and development in fiscal 2025.
What are Climb Bio's earnings per share?
Climb Bio earned $-0.89 per diluted share in fiscal 2025, compared with $-1.96 a year earlier.
When will Climb Bio report its next earnings?
Climb Bio is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Climb Bio's fiscal year end?
Climb Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.